Illumina introduces sequencing software for rare genetic diseases

By The Science Advisory Board staff writers

July 9, 2020 -- Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases.

Its TruSight software offers infrastructure that enables sample-to-report analysis for genetic disease testing, allowing researchers to go from 5 million variants to a small handful in a rapid, scalable way, according to Illumina.

On average, parents can spend five years trying to get correct diagnoses for their children. Whole genome sequencing offers the ability to reduce these diagnostic journeys, which cost an estimated $14 billion annually in the U.S., according to the firm.

Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to...
Imagia, Illumina partner to advance precision medicine
Healthcare artificial intelligence firm Imagia is partnering with Illumina on a project to further advance the development of precision medicine using...
Illumina acquires BlueBee to speed NGS
Illumina has acquired BlueBee, a Dutch genomics analysis software firm that originated as a spinoff from Delft University of Technology, in an effort...
Illumina makes SARS-CoV-2 NGS toolkit free of charge
Illumina is making its SARS-CoV-2 data toolkit, a suite of data analysis tools and workflow functionality, free for researchers researching the virus...
Illumina, IDbyDNA partner for COVID-19 surveillance
IDbyDNA and Illumina have partnered to bring next-generation sequencing (NGS) workflows to the global microbiology market to combat the COVID-19 pandemic....

Copyright © 2020 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter